Aratana Therapeutics, Inc. (NASDAQ:PETX) announced its earnings results on Thursday. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.03, Bloomberg Earnings reports. Aratana Therapeutics had a negative return on equity of 49.22% and a negative net margin of 358.55%. The firm had revenue of $6.16 million for the quarter, compared to analyst estimates of $6.47 million. During the same quarter last year, the firm posted ($0.38) EPS. The business’s revenue was up 1440.0% on a year-over-year basis.

Aratana Therapeutics (NASDAQ:PETX) traded up $0.90 during midday trading on Friday, reaching $6.54. The company had a trading volume of 1,016,982 shares, compared to its average volume of 292,910.

In related news, insider Ernst Heinen sold 10,000 shares of the stock in a transaction on Friday, September 15th. The stock was sold at an average price of $6.25, for a total value of $62,500.00. Following the completion of the transaction, the insider now directly owns 130,994 shares of the company’s stock, valued at approximately $818,712.50. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Peter Steven St sold 50,000 shares of the stock in a transaction on Monday, October 2nd. The shares were sold at an average price of $6.24, for a total value of $312,000.00. The disclosure for this sale can be found here. Over the last three months, insiders sold 70,000 shares of company stock valued at $435,600. 5.20% of the stock is owned by corporate insiders.

A number of brokerages have recently issued reports on PETX. Jefferies Group LLC reiterated a “buy” rating and set a $8.00 target price on shares of Aratana Therapeutics in a research report on Friday. BidaskClub lowered Aratana Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, July 19th. ValuEngine upgraded Aratana Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, July 25th. Lake Street Capital decreased their target price on Aratana Therapeutics from $15.00 to $10.00 and set a “buy” rating on the stock in a research report on Friday, August 25th. Finally, Zacks Investment Research lowered Aratana Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, July 13th. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average target price of $8.25.

COPYRIGHT VIOLATION WARNING: “Aratana Therapeutics, Inc. (PETX) Posts Earnings Results, Beats Estimates By $0.03 EPS” was first posted by American Banking News and is the property of of American Banking News. If you are accessing this story on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright law. The legal version of this story can be read at

About Aratana Therapeutics

Aratana Therapeutics, Inc is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company’s portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets.

Earnings History for Aratana Therapeutics (NASDAQ:PETX)

Receive News & Ratings for Aratana Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics Inc. and related companies with's FREE daily email newsletter.